Thomas Vermeulin

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study

Stéphane Leprêtre, Aurore Touzart, Thomas Vermeulin et al. · Journal of Clinical Oncology · 2015 · 97 citations

Medicine, Hematology, Oncology +15

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Jean‐Yves Blay, Sophie Boucher, Béatrice Le Vu et al. · ESMO Open · 2021 · 80 citations · Full text

Medicine, Oncology, Cancer Control +16

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

Sophie Frank, Matthieu Carton, Coraline Dubot et al. · The Breast · 2020 · 54 citations · Full text

Medicine, Geriatric Medicine, Oncology +12

Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial

V. Hébert, Thomas Vermeulin, L Tanguy et al. · British Journal of Dermatology · 2019 · 20 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15